Cite
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
MLA
Matsue, Kosei, et al. “Pomalidomide Alone or in Combination with Dexamethasone in Japanese Patients with Refractory or Relapsed and Refractory Multiple Myeloma.” Cancer Science, vol. 106, no. 11, Nov. 2015, pp. 1561–67. EBSCOhost, https://doi.org/10.1111/cas.12772.
APA
Matsue, K., Iwasaki, H., Chou, T., Tobinai, K., Sunami, K., Ogawa, Y., Kurihara, M., Midorikawa, S., Zaki, M., Doerr, T., & Iida, S. (2015). Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. Cancer Science, 106(11), 1561–1567. https://doi.org/10.1111/cas.12772
Chicago
Matsue, Kosei, Hiromi Iwasaki, Takaaki Chou, Kensei Tobinai, Kazutaka Sunami, Yoshiaki Ogawa, Mari Kurihara, et al. 2015. “Pomalidomide Alone or in Combination with Dexamethasone in Japanese Patients with Refractory or Relapsed and Refractory Multiple Myeloma.” Cancer Science 106 (11): 1561–67. doi:10.1111/cas.12772.